Recombinant Peptides as Biomarkers for Metastatic Breast Cancer Response
Annual summary rept. 25 Sep 2006-24 Sep 2007
VANDERBILT UNIV MEDICAL CENTER NASHVILLE TN
Pagination or Media Count:
The overall objective of this Proposal is to rapidly and non-invasively assess metastatic breast cancer susceptibility to tyrosine kinase inhibitors TKIs by use of recombinant peptides that bind within tumors. We will then identify the receptor to which the recombinant peptide binds. We propose that this receptor protein becomes unveiled following therapy. These recombinant peptides in turn can be labeled with internal emitters to provide a means of non-invasive monitoring of tumor responsiveness to therapy. We propose that the peptide will bind to receptors within the tumor microvasculature that are specifically induced in response to therapy and are not present in untreated endothelium. These aims will test the central hypothesis that non-invasive assessment of breast tumor susceptibility to therapy can be achieved by use of recombinant peptides selected from phage-displayed libraries.
- Medicine and Medical Research